Clinical Trial Service Unit

About: Clinical Trial Service Unit is a based out in . It is known for research contribution in the topics: Population & Stroke. The organization has 428 authors who have published 1387 publications receiving 181920 citations.

Risks of ischaemic heart disease and stroke in meat eaters, fish eaters, and vegetarians over 18 years of follow-up: results from the prospective EPIC-Oxford study

Abstract: Objective To examine the associations of vegetarianism with risks of ischaemic heart disease and stroke. Design Prospective cohort study. Setting The EPIC-Oxford study, a cohort in the United Kingdom with a large proportion of non-meat eaters, recruited across the country between 1993 and 2001. Participants 48 188 participants with no history of ischaemic heart disease, stroke, or angina (or cardiovascular disease) were classified into three distinct diet groups: meat eaters (participants who consumed meat, regardless of whether they consumed fish, dairy, or eggs; n=24 428), fish eaters (consumed fish but no meat; n=7506), and vegetarians including vegans (n=16 254), based on dietary information collected at baseline, and subsequently around 2010 (n=28 364). Main outcome measures Incident cases of ischaemic heart disease and stroke (including ischaemic and haemorrhagic types) identified through record linkage until 2016. Results Over 18.1 years of follow-up, 2820 cases of ischaemic heart disease and 1072 cases of total stroke (519 ischaemic stroke and 300 haemorrhagic stroke) were recorded. After adjusting for sociodemographic and lifestyle confounders, fish eaters and vegetarians had 13% (hazard ratio 0.87, 95% confidence interval 0.77 to 0.99) and 22% (0.78, 0.70 to 0.87) lower rates of ischaemic heart disease than meat eaters, respectively (P Conclusions In this prospective cohort in the UK, fish eaters and vegetarians had lower rates of ischaemic heart disease than meat eaters, although vegetarians had higher rates of haemorrhagic and total stroke.

One for the heart.

Abstract: “An ounce of whisky, please Sister,” or was it half an ounce or two ounces? I cannot remember now, but I know that I prescribed some tentatively after having sought the ward sister's opinion when I was called to my first patient with lobar pneumonia as a newly qualified house physician in 1937. There was nothing else to prescribe unless oxygen was needed. In the 19th century alcohol had been prescribed for many debilitating conditions, but its medicinal use was dying out except for people who were terminally ill, and there was certainly no idea that it might be of any use in preventing disease. Some people must have seen Pearl's report in 1926 of a U shaped relation between mortality and the consumption of alcoholic beverages, but it was totally ignored by the medical profession.1 The situation began to change soon after the second world war, with reports of an unusually low prevalence of coronary artery disease in patients found to have cirrhotic livers at necropsy.2 3 Necropsy series were, however, subject to many biases, and these reports excited little interest. Even in the 1970s, when case-control studies of people with and without myocardial infarcts4 and cohort studies of people with different personal characteristics5 began to report a reduced relative risk of myocardial infarction in people who drank small or moderate amounts of alcohol in comparison with non-drinkers, scant attention was paid to them. The belief that alcohol was bad for health was so ingrained that the idea that small amounts might be good for you was hard to envisage, and it is only in the past 10 years that cardiologists and specialists in preventive medicine have begun to take it seriously. The evidence for a beneficial effect is now massive.3 6 7 It …

Adolescents with acute lymphoblastic leukaemia: Emerging from the shadow of paediatric and adult treatment protocols

Abstract: Adolescents and young adults (AYA) with acute lymphoblastic leukaemia (ALL) constitute a distinct population from children and older adults Based on patterns of referral, they may be treated by either paediatric or adult oncologists As a group, AYA with ALL have a worse survival and event-free survival (EFS) compared to that achieved by younger children A systematic review of all published clinical trials, which provide data on treatment and outcome of adolescents with ALL, has been summarised in an effort to determine whether they should be treated on paediatric or adult type protocols Adolescents appear to have a consistent survival advantage when treated on paediatric regimens